Effect of topical application of diclofenac liposomal suspension on experimentally induced subcutaneous inflammatioin in horses

American Journal of Veterinary Research

Volumn 65, Issue 3, 2004, Pages 271-276

  Caldwell, Fred J ^a   Mueller, P O Eric ^a   Lynn, Randy C ^b   Budsberg, Steven C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Idexx Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; DICLOFENAC; LIPOSOME; PHENYLBUTAZONE; PROCAINE PENICILLIN; PROSTAGLANDIN E2;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; ENZYME IMMUNOASSAY; EXUDATE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; IMPLANT; INFLAMMATION; MALE; NONHUMAN; OINTMENT; PROSTAGLANDIN SYNTHESIS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE; SUSPENSION; TIME; TISSUE WATER; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DICLOFENAC; HORSE DISEASES; HORSES; IMMUNOENZYME TECHNIQUES; INFLAMMATION; LIPOSOMES; SUBCUTANEOUS TISSUE;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 1542515327     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.271     Document Type: Article

References (40)

1. National Animal Health Monitoring System. Lameness and laminitis in U.S. horses. Fort Collins, Colo: USDA, Animal and Plant Health Inspection Service, Veterinary Services, Centers for Epidemiology and Animal Health, 2000.
2. Wilson JH, Robinson RA, Jensen RC, et al. Equine soft tissue injuries associated with racing; descriptive statistics from American racetracks, in Proceedings. Dubai Int Equine Symp 1996;1-21.
3. Smith RK, Birch HL, Patterson-Kane J, et al. A review of the etiopathogenesis, and current proposed strategies for prevention, of superficial digital flexor tendinitis in the horse, in Proceedings. Am Assoc Equine Pract 2000;54-58.
4. Clark JO, Clark TP. Analgesia. Vet Clin North Am Equine Pract 1999;15:705-723.
5. Blikslager AT. Cyclooxygenase-2 inhibitors in equine practice. Compend Contin Educ Pract Vet 1999;21:548-550.
6. Kallings P. Nonsteroidal anti-inflammatory drugs. Vet Clin North Am Equine Pract 1993;9:523-541.
7. MacAllister CG. Nonsteroidal anti-inflammatory drugs: their mechanism of action and clinical uses in horses. Vet Med 1994; 89:237-240.
8. Collins LG, Tyler DE. Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2. Am J Vet Res 1985;46:1605-1615.
9. MacAllister CG, MacAllister CT. Treating and preventing the adverse effects of nonsteroidal anti-inflammatory drugs in horses. Vet Med 1994;89:241-246.
10. Scholer DW, Ku EC, Boettcher I, et al. Pharmacology of diclofenac sodium. Am J Med 1986;80:34-38.
11. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33:184-213.
12. Cordero JA, Camacho M, Obach R, et al. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm 2001;51:135-142.
13. Hui X, Hewitt PG, Poblete N, et al. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res 1998;15:1589-1595.
14. Hewitt PG, Poblete N, Wester RC, et al. In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharm Res 1998;15:988-992.
15. Calpena AC, Escribano E, San Martin H, et al. Influence of the formulation on the in vitro transdermal penetration of sodium diclofenac. Evaluation of the topical and systemic anti-inflammatory activity in the rat. Arzneimittelforschung 1999;49:1012-1017.
16. Higgins AJ, Lees P. Arachidonic acid metabolites in carrageenan-induced equine inflammatory exudate. J Vet Pharmacol Ther 1984; 7:65-72.
17. Higgins AJ, Lees P, Wright JA. Tissue-cage model for the collection of inflammatory exudate in ponies. Res Vet Sci 1984; 36:284-289.
18. Cheng Z, McKeller Q, Nolan A. Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. J Vet Pharmacol Ther 1998;21:315-321.
19. Sidhu P, Shojaee Aliabadi F, Andrews M, et al. Tissue chamber model of acute inflammation in farm animal species. Res Vet Sci 2003; 74:67-77.
20. Lees P, Landoni MF. Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. J Vet Pharmacol Ther 2002;25:433-448.
21. Higgins AJ, Lees P, Sedgwick AD. Development of equine models of inflammation. The Ciba-Geigy Prize for Research in Animal Health. Vet Rec 1987;120:517-522.
22. Landoni MF, Lees P. Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. Equine Vet J 1995;27:247-256.
23. Lees P, Aliabadi FS, Landoni MF. Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. J Vet Pharmacol Ther 2002;25:433-448.
24. Lees P, Higgins AJ. Flunixin inhibits prostaglandin E2 production in equine inflammation. Res Vet Sci 1984;37:347-349.
25. Lees P, Taylor JB, Higgins AJ, et al. Phenylbutazone and oxyphenbutazone distribution into tissue fluids in the horse. J Vet Pharmacol Ther 1986;9:204-212.
26. McKellar QA, Delatour P, Lees P. Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. J Vet Pharmacol Ther 1994;17:447-454.
27. McKellar QA, Lees P, Gettinby G. Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol 1994;253:191-200.
28. Clarke CR. Tissue-chamber modeling systems - applications in veterinary medicine. J Vet Pharmacol Ther 1989;12:349-368.
29. Higgins AJ, Lees P, Taylor JB. Influence of phenylbutazone on eicosanoid levels in equine acute inflammatory exudate. Cornell Vet 1984;74:198-207.
30. Moncrieff J. Extractionless determination of diclofenac sodium in serum using reversed-phase high-performance liquid chromatography with fluorometric detection. J Chromatogr 1992;577:185-189.
31. Zhang SY, Zou HQ, Zhang ZY, et al. High-performance liquid chromatographic method for the determination of diclofenac in serum and its pharmacokinetics in healthy volunteers. Yao Xue Xue Bao 1994;29:228-231.
32. Giagoudakis G, Markantonis SL. An alternative high-performance liquid chromatographic method for the determination of diclofenac and flurbiprofen in plasma. J Pharm Biomed Anal 1998; 17:897-901.
33. Elmquist WF, Chan KK, Sawchuk RJ. Transsynovial drug distribution: synovial mean transit time of diclofenac and other non-steroidal antiinflammatory drugs. Pharm Res 1994;11:1689-1697.
34. Ku EC, Lee W, Kothari HV, et al. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986;80:18-23.
35. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
36. Vincent CM, Laugel C, Marty JP. In vitro topical delivery of non-steroidal anti-inflammatory drugs through human skin. Arzneimittelforschung 1999;49:509-513.
37. Mezei M. Delivering the goods. Can Pharm J 1991; 124:132-141.
38. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 1994;268:144-151.
39. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs 1998;56:783-799.
40. Bhardwaj RK, Velpandian T, Kamal K, et al. Effect of liposomes on permeation of diclofenac through cadaver skin: in-vivo evaluation using animal models. Pharm Pharmacol Commun 2000;6:485-489.